Treating tumours with charged particles ranging from protons to light ions has many advantages, but has been little used because the dedicated accelerator facilities now planned or under construction are lacking.
Improving the quality of medical treat ment by means of new irradiation techno logies is one of the radiotherapist's con stant concerns. Each improvement in techniques to produce radiation and to control doses has led to an increase in the number of patients cured and to a reduc tion of adverse reactions. The replace ment of 200 keV x-rays by γ-rays from 60Co, which were in turn superseded by x-rays from electron linacs, illustrate the progress. The clinical benefits are essen tially due to an improved dose distribution of the radiation giving a lower dose to nor mal tissues for the same dose to a tumour. The latest techniques have made radio therapy the most widely used form of can cer treatment, given to two out of every three patients. Approximately 25 percent of cured cancer patients are still alive after five years thanks to radiotherapy alone, and a further 12 percent are cured by this form of treatment combined with other methods (a five-year survival is currently accepted as "proof of cure").
It was Robert Wilson, a student of Ernest Lawrence, who realized in 1946 at Harvard University in the USA that pro tons travel in almost straight lines and stop at a definite depth (they have the same "range"), and that this could lead to a new radiotherapeutic tool. He made radiotherapy one of the principle tasks of Francis J.M. Farley is a Consultant at the Labo ratoire du Cyclotron, Centre Antoine Lacas sagne, 227 avenue de la Lanterne, F-06200 Nice, one of 20 centres for cancer treatment in France. He studied at Cambridge University in the UK, receiving his Ph.D. in physics in 1949 after wartime research on radar and a year at the Chalk River Labs in Canada. He was suc cessively Senior Lecturer, Auckland University, New Zealand, a member of CERN staff and Dean of the Royal Military College, Shrivenham, UK, and has held several temporary ap pointments since 1982. Pierre Mandrillion heads the Laboratoire du Cyclotron at the Centre Antoine Lacassagne, Nice, where he was responsible for building the M EDICYC cyclotron, dedicated to proton and neutron therapy, and was Project Leader of the EULIM A initiative. He received his Ph.D. from Grenoble University in 1971 and then helped upgrade CERN's synchrocyclotron.
Fig. 1 -Depth-dose distribution for diffe rent radiations in Gy normalized to 100 at the peak (RX is x-rays).

Fig. 2 -Overlapping Bragg peaks for pro tons. A-E for mono-energetic protons of decreasing energies, which combine to give the total dose distribution S.
the Harvard cyclotron, which since 1961 has treated more patients than any other accelerator facility.
Following the successful pioneering work carried out with accelerators built for physics research, machines dedicated to this new radiotherapy are planned or are already under construction. Some 45 years after Wilson's pioneering work, the first hospital-based, dedicated, proton ac celerator is currently being commissioned at the Loma Linda University Medical Cen ter, USA, to treat 1000 patients each year.
We shall discuss the rationale for radio therapy based on light ions, which essen tially exploits two factors (improved phy sical selectivity and improved biological effectiveness [1] ), and the high energy accelerators and the beam delivery sys tems that are needed.
Physical Selectivity
The treatment of cancer with radiation is at present confined almost entirely to x-rays, γ-rays and electrons. However, these three types of radiation do not pro vide ideal dose distributions for treating tumours located deep inside the body. Fig. 1 shows the dose distribution achie ved in practice with electrons, soft x-rays, 60Co γ-rays and megavolt x-rays [2] ; the maximum dose is in the more superficial tissues and there would be a substantial dose beyond the tumour. Some unwanted radiation (not shown in the diagram) also passes outside the main beam.
The momentum transferred (force x time) to a quasi-stationary electron in the medium as an ion of charge Z and velocity v passes is proportional to Z/v. The energy transferred is therefore proportional to (Z/v)2. The ionization density (called LET, the linear energy transfer) rises as the ion slows down, until at the very end of the range the ionic charge is reduced by elec tron pick-up and the ionization falls rapidly to zero. This gives rise to the Bragg curve of ionization, seen in Fig. 1 for Ne ions, where the maximum dose is delivered in a narrow peak at the end of the range at a position that can be precisely controlled.
The dependence of the depth of pene tration on Z2 is also an important feature. It implies that for equal velocities the ioni zation density for oxygen ions (Z = 8, ato mic number A = 16) is 64 times greater than for protons. But as the kinetic energy is only 16 times larger (for the same velo city) the range will be four times smaller. So the Bragg peak for ions is more narrow ly concentrated at the end of the range than for protons. On the other hand, much higher energies are needed to achieve the range in tissue required to reach deepseated tumours.
The Bragg peak is only a few millimetres wide and must be broadened in order to give a uniform dose to a tumour several centimetres thick. Fig. 2 indicates sche- matically how by superposing beams of different energies [3] the peak can be enlarged in modulating the beam energy. In practice, the beam energy is most easily modulated by passing the beam through a variable absorber, for example, a disc of varying thickness which is rotated in the beam.
Typical Bragg peaks extended in this way, for various particles are given in Fig.  3 , taking into account the biological ef fects discussed below [4] . One should note that the dose in the "plateau" region in front of the extended Bragg peak de pends on the projectile, carbon being ap parently the best in that its plateau lies at the lowest dose. At longer ranges beyond the peak the effect of projectile fragmen tation can be seen. Some of the incoming ions break up as they pass through the target, giving fragments of roughly the same velocity. As these fragments usually carry a smaller electric charge, they pene trate further than the original projectile. Helium shows very little fragmentation, which becomes increasingly more severe on moving up the periodic table.
Another advantage of the light ions is that they travel in almost straight lines so very sharp collimation is possible. The lateral deflection due to multiple Coulomb scattering is reduced as the mass of the particle increases [5|. For carbon at a depth of 20 cm, the sideways scattering is only 1.5 mm, compared to 6.5 mm for protons. Electrons, on the other hand, are scattered so much that they are useful only for treating tumors located relatively close to the surface.
The inconvenience of the light ions is that much higher energies are required to obtain the 20 cm range needed to reach deep-seated tumours. Ranges for diffe rent light ions are plotted in Fig. 4 as a function of the kinetic energy per nucleon [6] to show how the required energy in creases sharply with the range. The energies and magnetic rigidities (= BR, where R is the bending radius in a magnetic field B, usually expressed in Tm) for a range of 20 cm are given in Table 1 . The magnetic rigidity fixes the bending radius of the particles, and therefore de termines the size of the accelerator and the beam delivery system. The number of particles per second (pps) required to deli ver a dose of 5 Gy over a volume of two litres in one minute is given in the final column.
There are, of course, fruitful applica tions for low energy accelerators in treat ing tumours which are less deep-seated, when precise dose localization is manda tory. An outstanding example is the use of 65 MeV protons (range 35 mm) for mela nomas of the eye, pioneered at Harvard University, USA, and now adopted at several other centres. Tumours are kept under control in almost all cases, and the irradiated eyes are conserved; over half the treated patients can see as well or better than before treatment [7] .
Biological Effectiveness
Different cells respond differently to radiation and a loosely defined parameter called "radiosensitivity" gives an indica tion of the response. The biological effects of light ions have been investigated for many years at Berkeley in the USA. Den sely ionizing particles, when they hit a cell, produce more concentrated local damage and have a more immediately lethal effect than the scattered minor lesions inflicted by weakly ionizing particles. As a result, radiation with a high linear energy transfer (LET) exhibits differences in the effects on biological tissue, when compared to low-LET radiation : these may be summarized as follows [1, 8] : -dividing cells are more sensitive; -some types of tumour cells are essen tially insensitive ; -large tumours de-oxygenated in the centre are less sensitive; -healthy cells can repair themselves if the radiation is divided into fractions ad ministered at intervals. For high-LET radiation, all cells respond more or less similarly and repair mecha nisms are less effective.
The last characteristic has important consequences for oxygen deficient (hy poxic) cells, which are, in general, less sensitive to radiation and are often pre sent at the centres of large, poorly vascularised, tumours (i.e., tumours lacking arteries and vessels to provide a good oxy gen supply). The effect of oxygen is less important for high-LET particles, see Fig. 5 [9], so hypoxic cells do not survive high-LET irradiation. It follows that high-LET, light ion treat ment is particularly useful for radioresis tant tumours, insensitive to normal x-rays. These will often be slowly growing tu mours with cells which only rarely under go cell division, or large, de-oxygenated tumours. On the other hand [1] , there is smaller difference between the sensitivi ties of cancerous and normal tissues so the beam must be very carefully delivered in order to impart the minimum possible dose to healthy cells. By the same token, because the amount of repair after irradia tion is smaller, fractionation schemes are less helpful in giving healthy tissue a chance to recover.
In summary, the increased ionization density of the light ions leads not only to a dose which increases with depth, but also to a change in the quality of the ra diation. Radiation at high-LET values has an increasing relative biological efficiency (RBE: the ratio of doses for a given survi val rate at different LET) up to about 200 keV per micron, beyond which the RBE decreases (Fig. 5) . Consequently, the bio-
Fig. 5 -Oxygen enhancement ratio (OER : the ratio of the radiosensitivities for well oxygenated relative to poorly oxygenated cells) and the relative biological efficiency (RBE : the ratio of doses for a given survival rate at different LET) versus linear energy energy transfer (LET). The range of LET available with H, C and Ne is indicated in the upper part.
logically effective dose at a depth relative to the dose at the entrance region in creases even more than the physical dose shown in Figs. 2 and 3 .
These physical and biological conside rations lead to the conclusion that the optimum ions for radiotherapy are in the range from helium to neon. He ions (and protons) are the most suitable when the tumour and adjacent tissues respond more effectively to low-LET radiation. For tumours displaying a superior response to high-LET, ions in the range C to Ne appear to be the best; the lower LET at entry will then help normal tissue be spared.
Accelerator Technology
The particle energies required for 20 cm range in tissue are given in Table 1 , to gether with the intensity needed to give a typical dose within about one minute. Selecting an accelerator for proton or ion therapy is not simple because the require ments lie in the overlap between large cy clotrons and small synchrotrons. Therapy has up to now usually been carried out with machines originally built for nuclear research, and adapted or used part of the time for medical treatment. However, more and more accelerators dedicated to medical use are coming on-stream.
For proton therapy at 60-90 MeV, useful for superficial and ocular cancers, several small cyclotrons are operating, and are supplied by at least two manufacturers. A new synchrotron has been installed for deeper treatments at the Loma Linda Hospital, USA, while several proton cyclo tron systems are being developed [10] .
lon therapy has been pioneered for over 12 years with the Bevalac at the Lawrence Berkeley Laboratory, California, USA [11] . This machine is primarily used for physics, and only about 100 patients can be trea ted each year. Based on the experience gained, several new machines dedicated to light ion therapy have been proposed : a large 100 M $US synchrotron is under construction at Chiba, Japan, ready for the start of operations in 1993, while a new synchrotron to replace the Bevalac has been proposed. In Europe, a feasibility study for a European Light Ion Medical Ac celerator (EULIMA) has been sponsored by the European Community and carried out in collaboration with CERN which acted as the host. The study defined and costed (≈ 50 M ECU) a synchrotron and treatment facilities to deliver a beam of oxygen ions at about 400 MeV/nucleon to 3000 patients each year [12] .
Beam delivery
In conventional radiotherapy with x-rays or γ-rays, the illuminated field is inevitably large and the end point of the range badly determined, for even if the x-rays are well collimated outside the body they spread by scattering to several centimetres at depth. In contrast, proton beams, and above all ion beams, can be exactly locali zed to a few millimetres in the lateral direc tion and to about 5 mm in range (see Fig.  1 ). Until now, the treatment area has been defined by collimators, but in principle a tumour can be treated more precisely by scanning in three dimensions over a de signated volume of arbitrary shape. The beam delivery system must accomplish this reliably and safely at reasonable cost so the requirements are : latéral (x-y) de flection by a fast magnet; variable range; variable exposure time to achieve a uni form biologically effective dose, as illu strated in Fig. 6 ; position sensitive moni tors; and a rapid shut-down in the event of a malfunction. A corollary is that the diag nostician must determine where the tu mour is with comparable precision. Fig. 6 also shows a typical treatment plan where the Bragg curve is placed suc cessively at various depths by adjusting the range. Each depth slice is scanned in the x-y plane over the tumour cross-sec tion, noting that when a distal slice (A in the figure) is treated, the centre of central slice (B) will receive some dose. This must be compensated for when slice B is trea ted by giving more dose at the edges than at the centre. Therefore, each slice gene rally requires a carefully computed nonuniform dose, and scanning across the x-y plane may be either continuous (a socalled raster scan) or intermittent (a pixel or spot scan) [10, 13] .
Pixel scanning
In pixel scanning, the target plane is treated at a triangular mesh of points ( Fig.  7 ) with spacing p: the beam spot has a Gaussian intensity with a standard devia tion s. If s ≥ 0.5 p the dose is uniform to 1.2%: the edge definition depends on s and is shown in Fig. 6 for s = 2.5 mm, p = 5 mm. These characteristics are suffi cient to delineate a cross-section of arbi trary shape by choosing which pixels to treat. The procedure would then be as fol lows: beam off -move spot to pixelbeam on until the desired dose is reached -repeat for the next pixel.
Continuous scanning strategies (Fig. 8 ) offer an alternative. The beam must be equipped with a fast switching magnet which dumps unwanted beam onto an absorber. With appropriate servo-control such a switch can be used, not only to turn the beam on and off, but also to regu late its intensity. One can then scan the tumour in a series of straight lines at uni form speed, adjusting the beam intensity appropriately at each point: when the spot falls outside the tumour, the beam would be turned off. Geometric considera- Fig. 8 -Raster scanning options for a beam equipped with a fast switching magnet. tions indicate that a parallel to-and-fro raster is more efficient than a zig-zag one for a field uniform to 2.8% (with a 2.5 mm spot size) where the raster spacing must be 5 mm vertically between turning points.
With a parallel to-and-fro raster, typical rise times required in the scanning mag nets (specified from zero to the full deflec tion of 150 mm) are t (horizontal) = 45 ms and t (vertical) = 300 ms.
The peak power required for the driving electronics is 2 J/t, where J is the stored energy of the magnetic field in joules. With careful beam design the magnetic energies can be kept low, say 75 J for the horizontal deflector and 300 J for the ver tical, so the peak powers P for the driving electronics would be modest : P (horizon tal, for 75 joules) = 3.3 KW ; P (vertical, for 300 joules) = 2.0 KW.
Scanning in range
The depth required in tissue is typically 5 to 20 cm, shallower tumours being trea ted with low energy proton machines. The corresponding particle energies are 80-180 MeV/nucleon for protons and alpha particles, 150-330 MeV/nucleon for car bon and 170-400 MeV/nucleon for oxy gen. There is no problem in varying the extraction energy using a synchrotron. A cyclotron, however, has a fixed extraction energy so here it will be necessary to reduce the energy by passing the beam through a slab of matter (a degrader) of variable thickness. Unfortunately, the de grader has several undesirable effects which must be analyzed, including : -increase of the beam phase space by multiple scattering; -increase of the momentum spread by energy straggling ; -fragmentation of incoming particles, giving lighter ions of roughly the same velocity with a longer range in the patient.
The increase in phase space in a degra der depends on its thickness as well as the scattering angle [14] , so the ideal material should have high density and low Z. The best compromise is diamond (not readily available in the required thickness); the next best are boron carbide and beryllium. For optimum results, the beam must be focussed onto the centre of the degrader at an optimum convergence angle.
With proton treatment, there is no pro blem of fragmentation, and the degrader can be placed just in front of the patient, so the beam line can be at fixed energy. With other ions, fragmentation inside the body is inevitable. How vital is it to elimi nate fragments produced in an external degrader ? This question is still debated. If necessary, the degrader could be placed far from the patient, so that most of the fragments will be lost in the subsequent bending magnets; but then the beam de sign becomes more complicated.
Conclusions
Interest in cancer treatment by protons and light ions is increasing rapidly. In the next decade, we can expect to see several more proton accelerators installed in hos pitals, and at least one centre for treat ment with ions.
Hospital-Based Proton Therapy
It is generally agreed that among the dif ferent kinds of radiation suitable for medical radiotherapy, high energy proton beams exhibit the best ballistic specificity for the selective destruction of cancer cells. Deve lopment has been hindered, however, by the size, cost and complexity of the equipment. To overcome these obstacles, a handful of companies are directing research at desig ning and supplying not only an accelerator, but also turn-key, easily operated, proton therapy facilities for hospitals.
Proton therapy has up to now been car ried out at essentially physics-based instal lations in Zurich, Uppsala, Paris, Nice, Harvard and Berkeley in the USA and Tsukuba and Chiba in Japan. The Commission of the European Community optimistically estimates that some 10 hospital-based faci lities are required in Europe over the next 10 years. Longer term interest will be determi ned by the demonstrated efficacy level of hospital-based proton therapy and whether doctors become convinced scanning sys tems are foolproof.
IBA Design
Ion Beam Applications (IBA) is among those companies with the most advanced To optimize system reliability, the company has selected a nonsuperconducting 230 MeV iso chronous cyclotron as the proton accelerator (see figure) . The mag net adopts a high field (3.09 T peak field, 2.165 T average at ex traction), deep-valley design using 190 kW in conventional coils. The upper half of the split cyclotron can be quickly raised one metre using hydraulic jacks to allow un restricted access. This feature, combined with a short pump-down time (30 min), minimizes downtime. To increase the reliabi lity of the system, the number of compo nents is reduced to a minimum.
An unique extraction scheme deflects particles in the hill region so that they pass through a specific "window" at the level of the closed pole edges beyond which the beam encounters a magnetic field gradient at a level below 2.2 T, thus avoiding the use of an expensive electro magnetic tunnel.
The cyclotron would feed 2-4 isocentric gantries of reduced size and cost which allow the the proton beam to scan a patient using both conventional scanning techni ques and a novel approach that links the axial sweep magnet field to a dose integra tor, guaranteeing uniform dose irrespective of small intensity fluctuations. For conven tional step ("voxal") scanning, the new gantry design makes it possible to achieve an infinite source-to-patient distance with a gantry of less than 3 m in radius.
